Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Hamdy A AzimKyrillus S ShohdyHagar ElghazawyMonica M SalibDoaa AlmeldinLoay KassemPublished in: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2022)
This analysis clearly shows that patients with PD-L1 positive TNBC respond better to neoadjuvant chemotherapy and are associated with better survival outcomes compared to patients with PD-L1 negative tumours. The newly distinct quadruple negative breast cancer (QNBC) subtype should be defined as the BC subtype with the poorest outcome in the non-metastatic setting, highlighting the need for more aggressive therapy approaches.